Would patients receiving targeted therapies be eligible for TTFields for brain metastases?

It is unknown whether NSCLC brain patients receiving targeted therapies should also receive TTFields. The most common patients would be those harboring EGFR mutations or ALK rearrangement. This would need to be studied and should not be presumed to be safe, as other unforeseen toxicities have occurr...

I agree with Dr. @Dr. First Last and Dr. @Dr. First Last. These patients were excluded from the study. That said, patients treated with therapies have good intracranial control relative to patients who don’t have molecular targets, so they may be less likely to benefit. There may be more of a role i...